zavegepant (Zavzpret)

From Aaushi
Jump to navigation Jump to search

Indications

  • FDA-approved for adults to treat acute migraine with or without aura (2023)

Dosage

Pharmacokinetics

  • rapid onset of action ~15 minutes

Mechanism of action

More general terms

References

  1. Lipton RB, Croop R, Stock DA et al Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo- controlled multicentre trial. Lancet Neurol. 2023 Mar;22(3):209-217. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36804093
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION ZAVZPRET <TM> (zavegepant) nasal spray https://labeling.pfizer.com/ShowLabeling.aspx